Monoclonal antibodies in treatment of multiple sclerosis

Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy

(2014) Daniel L. Keene et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

(2014) Manabu Araki et al.   Modern Rheumatology

Immunology of neuromyelitis optica: a T cell-B cell collaboration

(2013) Meike Mitsdoerffer et al.   Annals of the New York Academy of Sciences

Multiple sclerosis treatment and infectious issues: update 2013

(2013) A. Winkelmann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

(2013) P. S. Rommer et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

(2013) Gilles Edan et al.   CNS DRUGS

The benefits and risks of alemtuzumab in multiple sclerosis

(2013) Daniel Ontaneda et al.   Expert Review of Clinical Immunology

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients

(2013) Stefanie Dahlhaus et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

(2013) Sean J Pittock et al.   LANCET NEUROLOGY

Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy

(2013) Ilya Ayzenberg et al.   JAMA Neurology

The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications

(2013) Coralie Chanvillard et al.   Frontiers in Immunology

Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases

(2012) Paulus S. Rommer et al.   CURRENT PHARMACEUTICAL DESIGN

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

(2012) S. Rossi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Progressive multifocal leukoencephalopathy in autoimmune diseases

(2012) Elisabeth Palazzo et al.   JOINT BONE SPINE

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

(2012) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab

(2012) B.K. Kleinschmidt-DeMasters et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

(2012) L Daelman et al.   Multiple Sclerosis Journal

Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica

(2012) Bernd C. Kieseier et al.   JAMA Neurology

The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis

(2012) Isabela T. Borges et al.   Multiple Sclerosis and Related Disorders

Rituximab for Secondary Progressive Multiple Sclerosis

(2011) Paulus S. Rommer et al.   CNS DRUGS

More to come: Humoral immune responses in MS

(2011) Ruth Dobson et al.   JOURNAL OF NEUROIMMUNOLOGY

Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis

(2011) Ying Li et al.   JOURNAL OF NEUROIMMUNOLOGY

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

(2011) María José Magraner et al.   JOURNAL OF NEUROLOGY

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

(2011) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Intrathecal effects of daclizumab treatment of multiple sclerosis

(2011) B. Bielekova et al.   NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

(2011) Norio Chihara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

MS and the B cell controversy

(2010) Anne H. Cross et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

T helper 17 cells: discovery, function, and physiological trigger

(2010) Miriam Beer Torchinsky et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

(2010) J. S. CROWE et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis

(2010) Brandon A. Brown et al.   DRUG SAFETY

The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

(2010) Aaron Boster et al.   DRUGS

Alemtuzumab and multiple sclerosis: therapeutic application

(2010) Minagar Alireza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Ofatumumab

(2010) Bodi Zhang   mAbs

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

Immune reconstitution syndrome and the thyroid

(2009) Anthony Weetman   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Ocrelizumab: a step forward in the evolution of B-cell therapy

(2009) Fariha Kausar et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Monoclonal antibodies in the therapy of multiple sclerosis

(2009) P. S. Rommer et al.   JOURNAL OF NEUROLOGY

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

(2009) Monica A. Rojas et al.   Therapeutic Advances in Neurological Disorders

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Anti–Glomerular Basement Membrane Disease after Alemtuzumab

(2008) Menna R. Clatworthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE